辛伐他汀联合氯吡格雷对不稳定型心绞痛患者IL-6、hs—CRP及预后的影响

目的探讨辛伐他汀联合氯吡格雷治疗不稳定型心绞痛的临床疗效及对血清白介素6（IL-6）、高敏C反应蛋白（hs-CRP）水平的影响。方法本院2011年1月-2013年1月收治的105例不稳定型心绞痛（UAP），按照随机数字表法分为观察组53例与对照组52例，2组患者均给予常规治疗，对照组患者加用氯吡格雷片，观察组在对照组的基础上加用辛伐他汀，比较2组患者的临床疗效，IL-6、hs-CRP水平变化，以及出院后1个月内患者的心血管事件。结果①对照组与观察组临床总有效率分别为59．6％（31／52），86．8％（46／53），2组比较差异有统计学意义（P〈0．01）。②2组治疗后IL-6、hs—CRP水平均显著降低，差异有统计学意义（P〈0．05），治疗后2组IL-6、hs-CRP水平比较，差异有统计学意义（P〈0．05）。③2组患者随访30d，术后心绞痛再发生、心肌梗死发生率比较，差异有统计学意义（P〈0．05）。结论氯吡格雷联合辛伐他汀钙治疗不稳定型心绞痛临床效果显著，能有效改善IL-6、hs-CRP水平，安全性好。

Influence of simvastatin combined with clopidogrel on IL-6, hs-CRP and prognosis of patients with unstable angina pectoris

Objective To explore the influence of simvastatin combined with clopidogrel on prognosis and levels of IL-6 and hs-CRP CRP in patients with unstable angina pectoris （UAP）. Methods 105 patients with UAP from January 2011 to January 2013 were randomly divided into observation group （ n = 53） and control group （ n = 52）. On the basis of conventional treatment, control group was treated with clopidogrel, while observation group was treated with simvastatin plus clopidogrel. Clinical efficacy, levels of IL-6 and hs-CRP and cardiovascular events were compared between two groups. Results The total effective rate was 59.6 % in the control group, which was significantly lower than 86.8 % in the observation group （P 〈 0.01）. After treatment, levels of IL-6 and hs-CRP decreased significantly in both groups （P 〈 0.05）, and there were significant differences between two groups （P 〈 0.05）. All the patients were followed up for 30 days, and there were significant differences in aspect of incidence of postoperative angina and myocardial infarction between two groups （P 〈 0.05）. Conclusion Calcium clopidogrel combined with simvastatin can effectively improve levels of IL-6 and hs-CRP in the treatment of patients with UAP.